Successful treatment of a symptomatic uterine leiomyoma in a perimenopausal woman with a nonsteroidal aromatase inhibitor.
OBJECTIVE
To assess the management of symptomatic leiomyomas using a nonsteroidal aromatase inhibitor in perimenopausal women.


METHODS
Case report.


METHODS
Academic clinical practice.


METHODS
A 53-year-old woman suffering from recurrent urinary retention secondary to a uterine leiomyoma.


METHODS
Fadrozole, orally, 2 mg daily for 8 weeks and then 1 mg daily for 4 weeks.


METHODS
Measurements of leiomyoma volume, and levels of serum E(2), LH, and FSH.


RESULTS
Urinary retention resolved after 2 weeks of treatment and did not recur. Leiomyoma volume estimated by ultrasonography revealed a 71% reduction after 8 weeks of treatment.


CONCLUSIONS
Fadrozole was useful for the management of a symptomatic leiomyoma without transient deterioration of symptoms. Clinical trials are warranted.
Shozu
Makio
M
Department of Obstetrics and Gynecology, Kanazawa University School of Medicine, Japan. shozu@med.kanazawa-u.ac.jp
Murakami
Kouichi
K
Segawa
Tomoya
T
Kasai
Tadayuki
T
Inoue
Masaki
M
D047072:Aromatase Inhibitors; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D004958:Estradiol / Q000097:blood; D017316:Fadrozole / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D006801:Humans; D007889:Leiomyoma / Q000188:drug therapy* / Q000473:pathology; D007986:Luteinizing Hormone / Q000097:blood; D008593:Menopause; D008875:Middle Aged; D014594:Uterine Neoplasms / Q000188:drug therapy* / Q000473:pathology
D047072:Aromatase Inhibitors; D004791:Enzyme Inhibitors; D004958:Estradiol; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D017316:Fadrozole